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Abstract: Many skin diseases can occur in pregnant women. However, a few pruritic derma-
tological conditions are unique to pregnancy, including pemphigoid gestationis (PG). As PG 
is associated with severe morbidity for pregnant women and carries fetal risks, it is important 
for the clinician to quickly recognize this disease and refer it for dermatological evaluation and 
treatment. Herein, we review the pathogenesis, clinical characteristics, and management of PG.
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Introduction
Skin changes are common during pregnancy and can be divided into benign physi-
ologic skin changes due to normal hormonal/physiological changes,1 alterations in 
preexisting skin diseases because of immunohormonal changes, and pregnancy-specific 
dermatoses. Pregnancy-specific dermatoses represent a group of skin diseases that 
occur only during pregnancy and/or the immediate postpartum period. Severe pruritus 
represents the leading symptom commonly followed by a more widespread skin rash. 
Pregnancy-specific dermatoses include: pemphigoid gestationis (PG), polymorphic 
eruption of pregnancy (PEP), intrahepatic cholestasis of pregnancy (ICP), and atopic 
eruption of pregnancy (AEP).2
PG or gestational pemphigoid is a rare pregnancy-associated autoimmune skin 
disorder that is immunologically and clinically similar to the pemphigoid group of 
autoimmune blistering skin disorders. The pathogenesis is not yet fully established, 
but it belongs to the group of autoimmune skin disorders characterized by an immune 
response directed against different hemidesmosomal proteins affecting the adher-
ence between the dermis and epidermis causing blistering of the skin and mucosal 
membranes.3 Clinically, PG is characterized by intense pruritus and polymorphic skin 
eruptions. Pruritus can emerge before skin lesions and remain the only symptom. In 
more severe cases, skin lesions develop including erythematous patches and plaques, 
sometimes followed by urticarial rash and blisters. PG was previously termed herpes 
gestationis because the morphology of the blisters was similar to that of herpes, but 
it was shown not to be related to, or associated with, any prior or active herpes virus 
infection.
Some pregnancy-specific dermatoses carry considerable morbidity for pregnant 
women and can pose a significant risk to the fetus, such as premature birth and 
small-for-gestational age babies.4 It is therefore important to recognize and separate 
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these diseases from other benign pregnancy-associated skin 
changes. Pregnant women who present with a pruritic rash 
should always get immediate clinical evaluation, and if neces-
sary referred to a dermatologist. In this review, we elucidate 
the epidemiology, pathogenesis, clinical characteristics, 
treatment, and complications of PG.
Epidemiology and risk factors
General population studies on the epidemiology of PG are 
rare. Population-based studies have reported an annual inci-
dence ranging between 0.5 and 2.0 cases per 1 million people 
in France, Kuwait, Iran, and Germany.5–8 The incidence is 
estimated to be approximately 1 in 60,000 pregnancies.9,10 
The disease shows a worldwide distribution2,5,6,8,11,12 and no 
differences in ethnicity.13 The median age of affected women 
varies between 17 and 41 years, with a median age of onset 
around 26–32 years.11,14–16
PG mainly affects multiparous women in their second or 
third trimester of pregnancy, but onset in the first trimester or 
postpartum period is also reported.2,11,12,14,16–19 In a case series 
from the UK of women with PG including 117 pregnancies, 
the time of onset of PG ranged from 5 weeks of gestation to 
35 days postpartum. Of the 117 pregnancies, 21 (17.9%) pre-
sented in the first trimester, 40 (34.2%) presented in the sec-
ond trimester, and 40 (14.2%) presented in the third trimester, 
whereas in 16 (13.7%) the eruption began postpartum.14 In 
another case series from Austria including 21 pregnancies, 
15 (71%) had onset during the third trimester and 6 (29%) 
had an onset in the second trimester.2 The tendency for 
onset late in pregnancy was also confirmed in a third study 
from Saudi Arabia including 32 patients which showed that 
84% of women had onset of PG during the second or third 
trimester.11 Finally, in a smaller study from the UK including 
15 cases of PG, 8 women had onset in the third trimester, 2 
in the immediate postpartum period, whereas 4 presented in 
the second trimester.19
Recurrences in subsequent pregnancies are common and 
are usually more severe and with an earlier onset.1,15,17,20 Stud-
ies show recurrences in 33%–50% of patients,11,21 but cases 
of uninvolved or skipped pregnancies following a previously 
affected pregnancy are also reported. In a case study includ-
ing 25 patients with PG, 2 patients (8%) presented with an 
uninvolved pregnancy following a previously affected preg-
nancy.22 In another study of 87 patients with PG, 7 patients 
(8%) had an uninvolved pregnancy. This study also showed 
that skipped pregnancies could not be explained by a change 
in sexual partner or by the mother and the fetus being fully 
compatible at the DR locus.14 Why skipped pregnancies 
occur is still unknown. Both primiparous and multiparous 
women are affected, but most cases are reported to occur 
in multiparous women,11,14,19 although this is not congruent 
with a study of 23 cases where 56.5% of the women with PG 
were primiparous.15 There is no association between change 
in partner and development of PG,14 which was previously 
suggested.22
Pathogenesis
The pathogenesis of PG is considered to be similar to that 
of bullous pemphigoid, which is characterized by deposition 
of autoreactive antibodies directed against two hemidesmo-
somal proteins, BP180 and BP230, within the dermoepider-
mal junction, resulting in the formation of bullae and skin 
erosions.23 In PG, the first immune response occurs within 
the placenta. Placental trophoblasts and amniochorionic 
stromal cells show an abnormal expression of major histo-
compatibility complex (MHC) class II antigens24 allowing 
the presentation of BP180 (also known as BPAG1 or collagen 
XVII) protein to the maternal immune system. BP180 is a 
key structural protein of hemidesmosomes linking the epi-
dermis and dermis.25 BP180 is found in placental tissue, in 
fetal membranes, and also in the basement membrane zone 
of the skin. These specific proteins presented in the placenta 
are recognized as foreign, causing subsequent production of 
anti-placental IgG antibodies that cross-react with the same 
BP180 proteins in the skin. The binding of these antibodies to 
the basement membrane of the skin triggers an autoimmune 
response that consists of complement activation, deposi-
tion of immunecomplexes, consecutive chemoattraction 
of eosinophil granulocytes, and subsequent degranulation, 
resulting in tissue damage and blister formation.26
Immunogenesis is also found to play a role in the patho-
genesis of PG. It has been delineated that PG has a strong 
association with maternal MHC class II antigens haplotypes 
HLA-DR3 and HLA-DR4.27 These haplotypes have been 
shown to be more common in women with PG compared to 
a healthy control population. The presence of MHC II-class 
HLA-antigens DR3 was found in 61%–80% of patients com-
pared to only 22% in controls. DR4 was found in 52%–53% 
of patients compared to 33% in controls. Notably, the combi-
nation of these two haplotypes was found in 45% of patients 
compared to 3% of controls.27,28
Fluctuations in sex hormones are also proposed to play a 
role in the pathogenesis of PG. This is due to observations of 
a clinical flare or exacerbation during menstruation or follow-
ing administration of oral contraceptives postpartum,9,14,29,30 
but these observations are not consistent across studies.14
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Clinical features
PG initially presents with intense pruritus and inflamma-
tory skin lesions (Table 1). Pruritus can remain the only 
symptom, but mostly it develops into eruptive polymorphic 
skin lesions.2,15,16 Eruptive skin lesions initially present as 
urticarial papules and annular plaques, followed by vesicles 
and finally large tense bullae on an erythematous background 
(Figure 1). Skin lesions typically develop on the abdomen, 
characteristically involving the umbilical region (Figures 2 
and 3).2,11,14,19 In 90% of the cases, it later spreads to the rest of 
the abdomen (Figure 4), and in some patients the involvement 
of thighs (Figure 5), palms, and soles can be prominent.29 In 
a study of 23 patients, extremities were the most common 
site of involvement (100%).15 The mucous membranes and 
face are usually spared.18,31
Many patients experience remission during late pregnancy, 
sometimes followed by a flare immediately after delivery. 
The flare usually settles over a period of 4 weeks without 
Figure 1 Blister formation in pemhigoid gestationis.
Figure 2 Umbilical involvement in pemhigoid gestationis.
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recurrence.19 This supports the plausible pathogenic role of 
fluctuations in sex hormones. The disease is self-limiting, and 
after delivery the lesions usually resolve spontaneously within 
weeks to months. Rarely, a severe course with persistence 
of skin lesions over several years is seen.1,14 In a study of 87 
patients from the UK, the duration of active disease ranged from 
2 weeks postpartum to 12 years postpartum. The majority of 
patients were symptom free after 6 months, with a mean disease 
duration of 28.4 weeks and a median duration of 16 weeks.14 
Conversion from PG to BP should be considered in extremely 
persistent cases.32 Some patients experience a flare with the use 
of oral contraceptives; 6 (10.7%) out of 56 patients showed a 
flare with the use of oral contraceptives postpartum14 compared 
to previous studies suggesting a risk of exacerbation of 50%.9
Figure 3 Erythemtous, annular patches in pemhigoid gestationis.
Figure 4 Papular eruption in pemhigoid gestationis.
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Diagnosis
There are several ways to identify PG: clinical evaluation, 
histological findings, direct immunofluorescence (DIF) or 
indirect immunofluorescence (IIF), enzyme-linked immuno-
sorbent assay (ELISA), and C4d immunochemistry can all be 
used to diagnose PG. C4d immunochemistry is not standard 
of care and still considered experimental. DIF is the most 
frequently used method to detect PG, but recently other tests 
have been suggested to replace this method.
The histopathology of PG varies with the severity and the 
stage of the disease. In the early pre-bullous stage the classic 
histopathologic findings are urticarial lesions characterized 
by edema of the upper and mid-dermis with a perivascular 
infiltrate of lymphocytes, histiocytes, and eosinophils. In the 
later, bullous stage subepidermal split formations and bullae 
become evident.1 These histopathologic findings are not spe-
cific for PG and can also be seen in PEP. DIF demonstrates 
a linear deposition of C3 (complement 3) and IgG autoanti-
bodies at the dermoepidermal junction.18,29 C3 is reported in 
100% of cases, while IgG is seen in 25%–50% of cases.29 To 
avoid a skin biopsy, circulating autoantibodies can be detected 
using complement-binding tests, such as IIF or ELISA. IIF 
detects IgG autoantibodies targeting the basement membrane 
of the skin in 30%–100% of cases.2 ELISA would typically 
reveal circulating IgG antibodies against BP180, particularly 
against the NC16A domain of BP180. This test has shown a 
specificity of 94%–98% and a sensitivity of 86%–97% in the 
detection of BP180 antibodies in patients with PG.33–35 ELISA 
is suitable to monitor disease activity because serum levels 
of anti-BP180 NC16A correlate with disease severity.33,34 In 
a more recent study, routine immunohistochemistry showed 
a linear C4d immunoreactant deposition along the basement 
membrane in 100% of the patients with PG compared to 0% 
in patients with PEP.36 This method can be used to separate 
PG from the other pregnancy-specific dermatoses such as 
PEP, ICP, and AEP or other skin diseases.
Differential diagnoses
There are several skin disorders with similar symptoms and 
clinical presentation as the pregnancy-specific dermatoses 
that may present during pregnancy. Pruritus is the leading 
symptom in the pregnancy-specific dermatoses, but pruritus 
also occurs in more common diseases such as urticaria, 
drug hypersensitivity reactions, contact dermatitis and other 
eczemas, pityriasis rosea, pityriasis versicolor, and yeast 
folliculitis as well as other types of folliculitis, miliaria, and 
scabies, which should be considered as differential diagnoses 
and excluded before extended investigations are initiated.37 
The most important differential diagnoses for PG are the 
other pregnancy-specific dermatoses, which include AEP, 
PEP, and ICP. AEP is the most common pregnancy-specific 
dermatosis. It can be differentiated from PG by the time of 
onset. AEP presents early in the first or second trimester, 
whereas PG most commonly is seen during the second 
or third trimester. The most difficult disease to separate 
from PG is PEP. The symptoms are similar and the routine 
Figure 5 Urticaria-like eruption in pemhigoid gestationis.
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 histopathologic findings are indistinguishable, but in PEP the 
eruption often shows sparing of the umbilical region unlike 
PG, which often starts in the umbilicus. To differentiate PG 
from PEP, additional paraclinical tests such as DIF and skin 
biopsy are required.38 ICP presents with pruritus, and it has 
an onset during late pregnancy and is associated with fetal 
risks. In ICP, skin lesions are secondary to scratching, and 
jaundice may occur due to elevated levels of total serum bile 
acid, which separates it from PG.
Treatment
The aim of the treatment is to reduce pruritus and to prevent 
the advancement of new blisters. The treatment strategy 
depends on the severity of the disease. In mild cases, the use 
of class III or IV topical corticosteroids is sufficient. In more 
severe cases, oral corticosteroids are necessary.14 Preferred 
corticosteroids are prednisone and prednisolone. They are 
nonflourinated glucocorticoids that are inactivated by the 
11-β-hydroxylase enzyme of the placenta, resulting in a 
lowering of the steroid concentration crossing the placenta.39 
Minimum effective doses should be used to reduce the risk of 
side effects, starting with a daily dose of 0.5 mg/kg (or less), 
gradually tapered to a lower maintenance dose. If exacerba-
tion in the peripartum period occurs, the maintenance dose 
can be increased. The duration of treatment postpartum is 
individualized, but since the majority of patients are symp-
tom free after 6 months, it should be planned as part of the 
 therapeutic taper. In addition to corticosteroids, oral anti-
histamines can be used to control pruritus. Ultraviolet light 
therapy is relatively contraindicated as it may promote new 
blister formation. In unresponsive cases, patients may benefit 
from systemic immunoadsorption, a blood-purification tech-
nique that enables the selective removal of immunoglobulins 
from separated plasma through high-affinity adsorbers, and 
intravenous immunoglobulin (IVIG).40–44 Immunoadsorption 
is rare and not available in all countries. IVIG is a useful treat-
ment because of its availability and a good safety profile for 
the mother and the fetus, and this is therefore more standard 
of care. In case of persisting (postnatal) symptoms, systemic 
immunosuppressants such as cyclosporine A, dapsone, aza-
thioprine, or methotrexate might be beneficial.30 The use of 
topical steroids, regardless of potency, shows no significant 
increase in adverse pregnancy outcome.45 Low birth weight 
has been associated with the use of very potent topical ste-
roids in one study of poor methodological quality.45 Common 
side effects with the use of systemic immunosuppressants 
are nausea and loss of appetite, but there is no evidence of 
an increased risk of adverse pregnancy outcome.46 Use of 
cyclosporine A is associated with multiple side effects such 
as high blood pressure, renal insufficiency, bone marrow 
suppression, increased hair growth, headache, and cancer. 
If used during pregnancy, it can cause preterm birth but is 
considered not to be associated with birth defects. Dapsone 
is available both for topical and oral use. Severe side effects 
Table 1 Overview of PG
Clinical features Polymorphic skin lesions with intensely pruritic urticarial papules and annular plaques on an erythematous 
background. In severe cases, vesicles and large tense bullae develop.
Distribution Lesions characteristically develop in the umbilical region and later spread to the rest of the abdomen, thighs, palms, 
and soles.
Suggested pathogenesis An autoimmune response where complement-fixing IgG antibodies and complement C3 react with BP180 antigen 
on hemidesmosomes of the basement membrane of the skin and placenta, leading to tissue damage and blister 
formation.
Paraclinical diagnosis Histopathology: Urticarial lesions and dermal edema with an infiltrate of lymphocytes, eosinophils, and histiocytes.
DIF: Linear deposition of IgG and C3 complement at the BMZ
IIF: Detects IgG autoantibodies targeting the BMZ.
ELISA: Reveals IgG antibodies against NC16A domain of BP180.
Immunohistochemistry: A linear C4d immunoreactant deposition specific for PG.
Treatment Topical class III-IV corticosteroids.
Oral antihistamines
Oral corticosteroids at a daily dose of 0.5 mg/kg, gradually tapered to a low maintenance dose.
IVIG
Cyclosporine A, dapsone, azathioprine, or methotrexate (postpartum).
Fetal concerns Risk of small-for-gestational-age babies and preterm birth.
Drug toxicity of immunosuppressants.
Vesicular, urticarial skin lesions in newborns caused by a passive transfer of IgG antibodies (neonatal pemphigoid).
Abbreviations: BMZ, basement membrane zone; DIF, direct immunofluorescence; ELISA, enzyme-linked immunosorbent assay; IIF, indirect immunofluorescence; IVIG, 
intravenous immunoglobulin; PG, pemphigoid gestationis.
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of oral dapsone include hemolysis and liver inflammation. 
Dapsone should not be used during pregnancy because of 
insufficient data on side effects in pregnant women. Azathio-
prine may cause bone marrow suppression, liver impairment, 
and hypersensitivity reactions. Pregnant women should be 
carefully monitored if treated with azathioprine because of a 
small risk of birth defects. Methotrexate may cause elevated 
liver enzymes and bone marrow suppression. It should not 
be used during pregnancy or during breast-feeding because 
of a high teratogenic risk, embryotoxicity, and spontaneous 
abortion. In a study from the UK of 87 patients 13 (18.8%) 
out of 69 were treated with topical corticosteroids without 
systemic therapy, and 56 (81.2%) out of 69 required sys-
temic corticosteroids with initial doses of prednisolone in 
the range of 5–110 mg daily. Topical corticosteroids were 
inadequate once the vesico-bullous eruptions had developed. 
Most patients experienced remission with the use of systemic 
corticosteroids, but 15 (21.7%) required additional treatment 
with other systemic immunosuppressants. Two patients were 
unresponsive to treatment and eruptions persisted for more 
than 10 years.14 In a study from Saudi Arabia of 32 patients, 
75% responded well to oral corticosteroids. One patient 
needed IVIG. The vast majority of the patients (61%) became 
free of symptoms within 1–2 months of treatment.11 A study 
from the UK of 15 patients showed that eight women were 
treated with systemic corticosteroids with starting doses 
of prednisolone between 30 and 40 mg/d. The remaining 
women were treated with potent topical corticosteroids. Two 
women required additional immunosuppressant therapy for 
recalcitrant disease.19
Fetal concerns
Fetal prognosis is generally good, but PG is associated with 
fetal risks such as small-for-gestational-age babies and 
premature birth.47 Onset in the first or second trimester and 
the presence of blisters are found to be related to adverse 
pregnancy outcomes.4 Due to passive transfer of antibodies 
from the mother to the fetus, about 10% of newborns may 
develop mild urticaria-like or vesicular skin lesions (neonatal 
pemphigoid).28 The lesions are self-limiting, as within days 
to weeks antibody levels decrease.
Systemic use of corticosteroids does not appear to affect 
the fetal outcome.4 Methotrexate is toxic and contraindicated 
during pregnancy. Azathioprine and cyclosporine A can be 
used during pregnancy; however, drug toxicity in the mother 
related to medical treatment should be monitored closely 
because of an increased risk of birth defects and preterm 
birth.
Comorbidities
PG is associated with the autoimmune Graves’ (hyperthyroid-
ism) disease.14,48 In a study of 87 patients, the incidence of 
Graves’ disease in PG was significantly increased to 10.3% 
compared to 0.4% in the normal population.14 This can par-
tially be explained by the presence of HLA-DR3 and DR4.
Conclusion
PG is a rare autoimmune blistering skin disorder associated 
exclusively with pregnancy. Pathophysiologically, it is similar 
to bullous pemphigoid seen in elderly patients. The clinical 
presentation is characterized by intense pruritus and polymor-
phic skin lesions including blisters. The diagnosis is based 
upon clinical presentation and typical histopathological and 
laboratory findings. PG is self-limiting, but symptoms can be 
reduced with the use of topical and systemic corticosteroids, 
oral antihistamines, and systemic immunosuppressants. The 
prognosis is good, but PG is associated with fetal risks such 
as small-for-gestational-age babies and premature birth. 
Patients with PG should therefore be informed about the 
natural course of the disease and treatment possibilities. In 
addition, they should be informed about fetal prognosis, the 
possibility of relapse after delivery, relapse with the use of 
hormonal contraceptives, and the risk of relapse in subse-
quent pregnancies. Referral to dermatological evaluation is 
essential.
Consent
Written informed consent has been obtained from all patients 
for the publication of their images.
Disclosure
The authors report no conflicts of interest in this work.
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